Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 1999

View Archived Issues

Nycomed Amersham: 1999 half-year highlights include first mention of new product

Evacet/Taxotere combination therapy to be assessed in metastatic breast cancer

Endovasc reaches liposomal VEGF development agreement with Hermes Biosciences

Biomira's BLP25 cancer vaccine tested at higher dose and frequency

Orion: 5 NDAs under review in H1 1999

Gliadel Wafer approved in Germany for recurrent GBM

PolyMASC announces factor VIII research agreement with Bayer

CAT and HGS enter agreement for therapeutic antibody development

Centaur conducts phase IIa trials on two product candidates in Q2 1999

Melatonin antagonist S-22153 blocks phase-advancing effects of melatonin in vivo in mice

Oxigene licenses combretastatin prodrug from Arizona State University

Isotechnika advances development of new immunosuppressant

Texas Biotechnology highlights key developments for first half of 1999

Cordox shows cardioprotective effect during prolonged ischemia

Clot buster eptifibatide now on the market in U.K.

Neuronal calcium channel-modulating compounds from Lilly useful in treating CNS disorders

Potential new flu drugs described by BioCryst

Pfizer reveals new series of nicotinic acetylcholine receptor-modulating agents

Bayer research into metabotropic glutamate receptor ligands proves fruitful

K-252a derivatives with potential application in cancer and neurologic disorders

Quidel acquires Metra Biosystems, expands product line

Novel antibiotic series described in patent literature by HMR

COX-2 inhibitor research continues at Searle

STA-BX909: a promising new agent for BNCT

SunPharm to merge with GelTex

FDA approves Chiroscience's injectable anesthetic

Licensing opportunity from BTG: novel compounds for treating MRSA

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...